In our experience, neoadjuvant trastuzumab results in a complete response at the time of surgery for one-third of HER2-positive tumors, whereas one-third of patients are left with significant tumor burdentumors (J.J., and A.G. unpublished). This evidence concerns the gene ERBB2 and neoplasm.